A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Idebenone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms DELOS
- Sponsors Santhera Pharmaceuticals
- 29 May 2020 According to a Santhera Pharmaceuticals media release, the company will host a conference call today to discuss this update.
- 29 May 2020 According to a Santhera Pharmaceuticals media release, the CHMP opinion is expected in Q4 2020.
- 29 May 2020 According to a Santhera Pharmaceuticals media release, the company EMA's CHMP has granted a requested extension of the clock-stop in the regulatory procedure for its conditional marketing authorization (CMA) application for Puldysa (idebenone) in Duchenne muscular dystrophy (DMD) to evaluate the potential of conducting an interim analysis to test overwhelming efficacy of its SIDEROS study with a view of including the data in the review procedure and potentially complete the SIDEROS trial early.